心脏骤停后去甲肾上腺素与肾上腺素的比较:系统评价与Meta分析
该系统评价与Meta分析检索多个数据库,纳入6项观察性或随机研究、共3458例成人心脏骤停复苏后患者,比较肾上腺素与去甲肾上腺素对复苏后休克的作用。去甲肾上腺素组1833例(53%),再发心脏骤停共703例中287例(41%)发生于去甲肾上腺素组。去甲肾上腺素与再发心脏骤停几率降低63%相关(OR 0.47,95%CI 0.24-0.92,P=0.03,I²=89%)。出院生存率(OR 2.04,95%CI 0.93-4.47)和出院时不良神经功能结局(OR 1.72,95%CI 0.92-3.22)两组无统计学差异。作者认为研究数量少、异质性高,需设计良好的未来研究验证。
要点
- 在心脏骤停复苏后休克成人中,去甲肾上腺素组再发心脏骤停风险低于肾上腺素组(OR 0.47,95%CI 0.24-0.92,P=0.03)。
- 去甲肾上腺素组再发心脏骤停287例,占全部703例再发心脏骤停的41%;去甲肾上腺素组共1833例(53%)。
- 出院生存率两组无统计学差异(OR 2.04,95%CI 0.93-4.47)。
- 出院时不良神经功能结局两组无统计学差异(OR 1.72,95%CI 0.92-3.22)。
- 研究异质性高(I²=89%),作者认为需设计良好的未来研究验证这些发现。
适用人群与场景
- 成人心脏骤停后获得自主循环恢复(ROSC)并出现复苏后休克的患者。
研究设计与关键结果
- 系统评价与Meta分析,纳入6项观察性或随机研究,共3458例患者,平均年龄64(±3)岁,男性2188例(63%)。
- 去甲肾上腺素组1833例(53%);再发心脏骤停共703例,其中去甲肾上腺素组287例(41%)。
- 去甲肾上腺素与再发心脏骤停几率降低63%相关(OR 0.47,95%CI 0.24-0.92,P=0.03,I²=89%)。
- 出院生存率两组无统计学差异(OR 2.04,95%CI 0.93-4.47)。
- 出院时不良神经功能结局两组无统计学差异(OR 1.72,95%CI 0.92-3.22)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入观察性或随机研究。
- 异质性高(I²=89%),作者认为需设计良好的未来研究验证这些发现。
对床旁实践的改变
- 作者认为,在心脏骤停复苏后患者中使用去甲肾上腺素与再发心脏骤停几率降低相关,但研究数量少且异质性高,需未来研究验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Patients who obtain return of spontaneous circulation (ROSC) after cardiac arrest often experience post-resuscitation hypotension, typically managed with epinephrine (EPI). However, recent research suggests that norepinephrine (NE) may improve patient outcomes. This systematic review and meta-analysis evaluates the effectiveness of EPI versus NE in managing post-resuscitative shock in patients who achieve ROSC.
METHODS: A systematic literature search in PubMed, Medline, Scopus, EMBASE, and Cochrane CENTRAL was performed. Observational or randomized studies on adults comparing EPI to NE after cardiac arrest were included in analysis. Outcomes were analyzed via random-effects meta-analysis and included rate of re-arrest during hospital stay, survival to discharge, and functional neurological outcome at discharge.
RESULTS: After screening 1217 studies, we analyzed 6 studies, which involved 3458 patients, with mean (+/- SD) age of 64 (+/- 3) years, and 2188 (63 %) were male. The NE group consisted of 1833 (53 %) patients and 287 (41 %) of the total 703 re-arrest. Patients receiving NE were associated with 63 % lower odds of having recurrent arrest (OR 0.47, 95 % CI 0.24-0.92, P = 0.03, I2 = 89 %). There was no statistical difference for rates of hospital survival (OR 2.04, 95 % 0.93-4.47) or discharge with unfavorable neurological outcome (OR 1.72, 95 % CI 0.92-3.22).
CONCLUSIONS: Among a small number of studies, norepinephrine use in post-cardiac arrest patients was associated with lower odds of recurrent cardiac arrest. However, high study heterogeneity highlights the need for well-designed future research to validate these findings.
参考来源
- Williams CA, Pourmand A, Hintze T, et al. Norepinephrine versus epinephrine after cardiac arrest: A systematic review and meta-analysis. Am J Emerg Med. 2025. PMID: 40440817. doi:10.1016/j.ajem.2025.05.038
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。